In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis
Volume 20, Issue 2, February 2020, Page 173-182 .
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Marco Galluzzo Simone D ’Adamio Dionisio Silvaggio Paolo Lombardo Luca Bianchi Marina Talamonti Source Type: research
More News: Drugs & Pharmacology | Psoriasis